Menu Close

Updated Information and Guidelines for Evaluation of Patients for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection

Premier Communications

SafetyShare® newsletter brought to you by the Premier Safety Institute®
June 17, 2015


The Republic of Korea has an ongoing outbreak of Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Infection involving 108 cases as of June 11, 2015. This represents the largest single outbreak of MERS-CoV outside of the Arabian Peninsula.
This issue of SafetyShare includes a CDC HEALTH ADVISORY on MERS-Co-V with guidance on who should be evaluated
and tested and infection prevention and control guidance for hospitalized patients with possible MERS-CoV.


FROM: CDC Health Alert Network

June 11, 2015

Updated Information and Guidelines for Evaluation of Patients for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection


The Centers for Disease Control and Prevention (CDC) continues to work with the World Health Organization (WHO) and other partners to closely monitor
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) globally, including the cases of MERS-CoV infection recently reported by China and the Republic
of Korea, to better understand the risks to public health. The purpose of this HAN Advisory is to provide updated guidance to state health departments
and healthcare providers in the evaluation of patients for MERS-CoV infection, which have been revised in light of the current situation in the
Republic of Korea. Healthcare providers and public health officials should maintain awareness of the need to consider MERS-CoV infection in ill persons
who have recently traveled from countries in or near the Arabian Peninsula


or in the Republic of Korea as outlined in the guidance below. Please disseminate this information to healthcare providers, especially infectious
diseases specialists, intensive care physicians, internists, infection preventionists, and to emergency departments and microbiology laboratories.


On May 20, 2015, the Republic of Korea (Korea) reported to WHO a case of laboratory-confirmed2 MERS-CoV infection, the first case in what is now
the largest outbreak of MERS-CoV outside of the Arabian Peninsula1. The index case is a 68 year-old male who travelled to Bahrain, United Arab
Emirates (UAE), Kingdom of Saudi Arabia (KSA), and Qatar, prior to returning to Korea on May 4. He subsequently became ill and sought medical care at
several healthcare facilities before being diagnosed with MERS-CoV on May 20. Since then, as of June 10, 107 additional laboratory-confirmed2
cases of MERS-CoV have been identified according to the Republic of Korea Ministry of Health, for a total of 108 cases, including 9 deaths; WHO has
confirmed 64 of these cases and 5 deaths. One of these cases is a contact associated with this outbreak who travelled from Korea to China on May 26 while
symptomatic, tested positive for MERS-CoV in China on May 29, and is the first reported case from China; no other countries have reported any cases of
MERS-CoV infection linked to this outbreak. According to available WHO reports, all reported cases are epidemiologically linked to the index case, with
transmission limited to other patients, healthcare workers, and visitors in healthcare facilities where case-patients received care. This outbreak is still
under investigation, and active contact tracing and prevention measures are ongoing in Korea and China. CDC is closely monitoring the situation to better
understand the public health risks associated with this outbreak.

First identified and reported to cause severe acute respiratory illness in September 2012, MERS-CoV has caused infections worldwide, with 25 countries
reporting cases to date. As of June 10, 2015, 1,219 laboratory-confirmed2 cases of MERS-CoV infection have been reported to and confirmed by
WHO, including at least 449 (37%) deaths. The majority of cases (~85%) have been reported from KSA. All reported cases have been directly or indirectly
linked through travel or residence to nine countries: KSA, UAE, Qatar, Jordan, Oman, Kuwait, Yemen, Lebanon, and Iran. In the United States (US),
nationwide surveillance for MERS-CoV has been ongoing since 2012, and as of June 5, 2015, 45 states have submitted specimens to CDC or conducted their own
testing for MERS-CoV based on CDC criteria available in their current form at
. Of the 584 total persons tested in the US, two patients tested positive for MERS-CoV in May 2014 and were determined to be imported cases from KSA; the
remaining 582 patients tested negative.


CDC continues to recommend that healthcare providers and health departments throughout the US be prepared to detect and manage cases of MERS. Healthcare
providers should continue to routinely ask their patients about their travel history and healthcare facility exposure and to consider a diagnosis of
MERS-CoV infection in persons who meet the criteria for patient under investigation (PUI), which has been revised to include considerations of recently
being in a Korean healthcare facility and is available at
. Specifically, persons who meet the following updated criteria for PUI should be evaluated for MERS-CoV infection in addition to other common respiratory
pathogens3 and reported immediately to state and local health departments:


A. Fever AND pneumonia or acute respiratory distress syndrome (based on clinical or radiologic evidence) AND one of the following:

  • A history of travel from countries in or near the Arabian Peninsula1 within 14 days before symptom onset, OR close contact 4 with a symptomatic traveler who developed fever and acute respiratory illness (not necessarily pneumonia) within 14 days
    after traveling from countries in or near the Arabian Peninsula1, OR
  • A history of being in a healthcare facility (as a patient, worker, or visitor) in the Republic of Korea within 14 days before symptom
    onset, OR
  • A member of a cluster of patients with severe acute respiratory illness (e.g., fever and pneumonia requiring hospitalization) of
    unknown etiology in which MERS-CoV is being evaluated, in consultation with state and local health departments in the US,


B. Fever AND symptoms of respiratory illness (not necessarily pneumonia; e.g., cough, shortness of breath) AND a history of being in a
healthcare facility (as a patient, worker, or visitor) within 14 days before symptom onset in a country or territory in or near the Arabian
Peninsula1 in which recent healthcare-associated cases of MERS have been identified,


C. Fever OR symptoms of respiratory illness (not necessarily pneumonia; e.g., cough, shortness of breath) AND close contact4
with a confirmed MERS case while the case was ill.


The above criteria serve as guidance for testing; however, patients should be evaluated and discussed with public health departments on a case-by-case
basis if their clinical presentation or exposure history is equivocal (e.g., uncertain history of health care exposure).

Health departments should immediately report PUIs to CDC using the MERS PUI short form available at
, and should send completed investigation short forms by fax to CDC at 770-488-7107, or attach the short form to an email and send to with the subject line: MERS Patient Form.

Recommendations may be updated as additional data become available. Guidance on the evaluation of patients for MERS-CoV infection, clinical specimen
collection and testing, infection control, and home care and isolation measures is available on the CDC MERS website at

Healthcare providers should adhere to recommended infection control measures, including standard, contact, and airborne precautions while managing patients
in healthcare settings who are PUIs or confirmed cases of MERS-CoV infection. Updated guidance on MERS-CoV infection control in healthcare settings is
available at

For PUIs, CDC recommends collecting multiple specimens from different sites after symptom onset for testing with the CDC MERS-CoV rRT-PCR assay, including
a lower respiratory specimen (e.g., sputum, broncheoalveolar lavage fluid, or tracheal aspirate), a nasopharyngeal/oropharyngeal swab, and serum.
Additional guidance for collection, handling, and testing of clinical specimens is available at

CDC interim guidance to prevent MERS-CoV from spreading in homes and communities in the US is available at

No vaccine or specific treatment for MERS-CoV infection is available; care is supportive. WHO has posted guidance for clinical management of MERS patients

Countries considered in the Arabian Peninsula and neighboring include: Bahrain; Iraq; Iran; Israel, the West Bank, and Gaza; Jordan; Kuwait; Lebanon; Oman;
Qatar; Saudi Arabia; Syria; the United Arab Emirates; and Yemen.

Confirmatory laboratory testing requires a positive polymerase chain reaction test result on at least two specific genomic targets for MERS-CoV or a single
positive target with sequencing on a second.

Examples of respiratory pathogens causing community-acquired pneumonia include influenza A and B, respiratory syncytial virus, Streptococcus pneumoniae, and Legionella pneumophila.

Close contact is defined as: a) being within approximately 6 feet (2 meters) or within the room or care area for a prolonged period of time (e.g.,
healthcare personnel, household members) while not wearing recommended personal protective equipment (i.e., gowns, gloves, respirator, eye protection-see
); or b) having direct contact with infectious secretions (e.g., being coughed on) while not wearing recommended personal protective equipment (i.e.,
gowns, gloves, respirator, eye protection-see
). Data to inform the definition of close contact are limited. At this time, brief interactions, such as walking by a person, are considered low risk and
do not constitute close contact.

For more information:

For additional information, please consult the CDC coronavirus website at:
. State and local health departments with questions should contact CDC’s Emergency Operations Center (770-488-7100).



Safety Institute

Subscribe  – 

Contact  – 

Topics  –

Editorial team

You may forward this newsletter to your colleagues.

If you would like to reprint any of these stories,

please cite the “SafetyShare newsletter, Premier Inc.” as your source
and send an email to and alert us. Thank you.